Last reviewed · How we verify
Timodyne (MEFEXAMIDE)
Timodyne (generic name: MEFEXAMIDE) is a drug. It is currently in Phase 2 development.
Timodyne works by interacting with a specific target in the body to produce a therapeutic effect.
Timodyne (MEFEXAMIDE) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. Further information on its pharmacokinetics, safety, and efficacy is not available. As a result, it is not possible to provide a comprehensive summary of this drug. More research is needed to understand its potential uses and risks.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEFEXAMIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Unfortunately, the exact mechanism of action of Timodyne is not well understood, and more research is needed to determine how it produces its effects. In general, small molecule drugs like Timodyne are designed to bind to specific proteins or receptors in the body, which can alter the way that cells function and communicate with each other. This can lead to changes in various physiological processes, such as the regulation of chemical signals or the contraction of muscles.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timodyne CI brief — competitive landscape report
- Timodyne updates RSS · CI watch RSS
Frequently asked questions about Timodyne
What is Timodyne?
How does Timodyne work?
What is the generic name of Timodyne?
What development phase is Timodyne in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing